TENSIVE SRL

Tensive is an Italian clinical-stage medical device company developing advanced biomaterial solutions for breast reconstruction. Its REGENERA™ and SOFTAG™ products are bioresorbable biopolymer scaffolds designed to replace lost volume and support the growth of new tissue, with the goal of enabling natural breast reconstruction and tissue marking after lumpectomy. The company’s approach aims to provide a minimally invasive, permanent and safe option for patients, including those undergoing breast cancer treatment.

Tensive reports that its first-in-human study demonstrated safety and encouraging clinical outcomes in benign tumor resections. A pivotal trial involving 94 breast cancer patients is ongoing, with the company citing positive performance indicators and high satisfaction among patients and surgeons. The technology remains under development, and the breast implants are not commercially available; first approvals are expected in early 2027. Based in Milan, Tensive also conducts clinical research and shares scientific findings through publications and medical events. Its work is supported by a portfolio of issued and pending patents and investor funding.